News
News

News

AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors
April 25, 2022  •  AmberGen announces that Dr. Michael Easterling, PhD, Director of Imaging for Bruker’s Life Science Mass Spectrometry Division, will join the company’s Board of Directors.
AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild
April 25, 2022  •  The Board of Directors has appointed John Gillespie as President and CEO of AmberGen.  Dr. Kenneth J. Rothschild, Founder and longtime CEO will become Executive ...
AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC)
April 8, 2022  •  Transforming Multiomics Spatial Tissue Biology with the Power of MALDI Mass Spectrometry for Imaging Targeted Proteins, Lipids, Glycans and Metabolites PRESS RELEASE WATERTOWN, Massachusetts, April ...
Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session
March 25, 2022  •  Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session at US HUPO ...
The paper “Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues” was published in The Journal of the American Society for Mass Spectrometry
February 25, 2022  •  The paper “Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues” with co-authors Gargey Yagnik PhD., Ziying Liu MD, Kenneth J. Rothschild, PhD., and Mark ...
Dr. Mark Lim of AmberGen gave an invited presentation sponsored by Bruker at the European Association for Cancer Research (EACR)
February 25, 2022  •  Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session at US HUPO ...
Dr. Mark Lim Presentation at Bruker’s “Virtual eXceed Symposia and Breakfast Workshops: Expanding the Horizons of Singe Cell Research” during ASMS 2021 in Philadelphia.
October 25, 2021  •  Dr. Mark Lim had the opportunity to give a presentation at Bruker’s “Virtual eXceed Symposia and Breakfast Workshops: Expanding the Horizons of Singe Cell Research” ...
AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA
July 25, 2020  •  AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA to develop a blood-based Alzheimer Diagnostic Assay based on its proprietary PC-PURE technology
Dr. Gargey Yagnik, PhD is appointed as Director of Mass Spectrometry
November 25, 2019  •  Dr. Gargey Yagnik, PhD is appointed as Director of Mass Spectrometry.
AmberGen awarded a $2 million, 2-year Phase II SBIR grant from NIH-NCI
September 25, 2019  •  AmberGen was awarded a $2 million, 2-year Phase II SBIR grant from NIH-NCI to develop its MALDI-IHC technology for high-plex molecular imaging of cancer tissues.
AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics
October 25, 2018  •  AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics.
AmberGen receives US Patent 10,060,912 for global proteomic screening of random bead-arrays using mass spectrometric imaging
August 25, 2018  •  AmberGen receives US Patent 10,060,912 for global proteomic screening of random bead-arrays using mass spectrometric imaging.
AmberGen receives US Patent 9,910,034 for its innovative PC-PURE technology for photo-affinity biomarker enrichment
March 25, 2018  •  AmberGen receives US Patent 9,910,034 for its innovative PC-PURE technology for photo-affinity biomarker enrichment.
AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing
March 25, 2018  • 
Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)
February 25, 2018  •  Read Paper
AmberGen awarded $2 million, 2-year Phase IIb SBIR grant from NIH-NIAID to further develop its PC-PURE™-assisted, multiplex, in vitro AllerBead™ assay which uses finger-stick blood for the highly multiplex quantification of allergen-specific IgE
January 25, 2018  • 
AmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays
February 1, 2017  • 
Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.
January 1, 2017  • 
AmberGen awarded two US Patents (9,513,285 and 9,523,680) providing broad coverage for its Bead-AMS™ technologies
December 1, 2016  • 
AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.
December 1, 2016  • 
AmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage
November 7, 2016  • 
AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale
September 27, 2016  • 
AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers
July 27, 2016  • 
Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding
May 27, 2016  •  https://www.ncbi.nlm.nih.gov/pubmed/27194112
AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays
May 15, 2016  • 
John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development
July 27, 2015  • 
Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH
February 27, 2015  •  https://www.ncbi.nlm.nih.gov/pubmed/25243383
AmberGen receives US Patent 8,932,879 for its pioneering PC-PRINT™ technology
January 27, 2015  • 
AmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays
December 27, 2014  • 
AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)
October 27, 2014  • 
AmberGen awarded 2-year Phase II SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions
July 27, 2014  • 
AmberGen awarded 3-year Phase II SBIR grant from NIH-NIAID for development of a multiplex in vitro pediatric allergy test
February 27, 2014  • 
Paper published in Rapid Communications in Mass Spectrometry “Correlated matrix-assisted laser desorption/ionization mass spectrometry and fluorescent imaging of photocleavable peptide-coded random bead-arrays” describing proteomic applications of Bead-AMS™
January 27, 2014  •  https://www.ncbi.nlm.nih.gov/pubmed/24285390
Paper published in Journal of Immunological Methods “Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer” detailing the development of a serological assay for colorectal cancer biomarkers based on the novel use of the VeraCode™ multiplex bead assay system
December 27, 2013  •  https://www.ncbi.nlm.nih.gov/pubmed/24161315
AmberGen receives US Patent 8,507,648 for novel method of detecting protease activity using mass spectrometry
August 27, 2013  • 
AmberGen receives US Patent 8,486,634 for novel method of detecting DNA methylation using solid-phase PCR
July 27, 2013  • 
AmberGen receives US Patent 8,481,263 for creating self-assembled bead-protein libraries by solid-phase PCR and nascent protein expression
July 15, 2013  • 
AmberGen receives US Patent 8,288,098 for a novel method of DNA sequencing using nucleotides having cleavable detectable labels
October 27, 2012  • 
AmberGen receives US Patent 8,278,045 for detecting chain truncation mutations which cause breast and colorectal cancer
October 15, 2012  • 
AmberGen awarded Phase I SBIR grant for the application of photocleavable bead technology to glycomics
September 27, 2012  • 
AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins
April 27, 2012  • 
AmberGen awarded 3-year Phase II SBIR grant for discovery of tumor autoantigen biomarkers using Bead-AMS™ proteomic array technology
April 15, 2012  • 
AmberGen and Massachusetts General Hospital license the use of two novel autoantigen biomarkers for autoimmune liver disease to INOVA Diagnostics
March 27, 2012  •  http://www.marketwired.com/press-release/ambergen-mass-general-license-two-novel-autoantigen-biomarkers-autoimmune-liver-disease-1631270.htm
AmberGen awarded Phase I SBIR grant for development of a multiplex in vitro pediatric allergy test
March 15, 2012  • 
AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection
February 27, 2012  • 
Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers
November 27, 2011  •  AmberGen-SomaLogic Press Release
AmberGen awarded Phase I SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions
September 27, 2011  • 
AmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins
March 27, 2011  • 
AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic
February 27, 2011  • 
Promega distributes AmberGen’s fluorescent tRNA based protein engineering technology
January 29, 2011  •  https://www.promega.com/products/protein-expression/protein-labeling-and-detection/fluorotect-greenlys-in-vitro-translation-labeling-system/
Thermo-Fisher sells AmberGen’s PC-Biotin-NHS reagent
January 28, 2011  •  https://www.fishersci.com/shop/products/pc-biotin-nhs-5mg/nc1042383
Glen Research distributes AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents
January 27, 2011  •  http://www.glenresearch.com/GlenReports/GR14-14.html
Link Technologies Ltd. offers AmberGen’s Photocleavable Phosphoramidite DNA-labeling reagents in Europe
January 26, 2011  •  http://www.linktech.co.uk/products/modifiers/photocleavable_modifiers